Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
May 13, 2026, 07:35Ifeanyichukwu Ifechidere: Why DIC is the Condition That Humbles even the Most Experienced Scientists
-
May 13, 2026, 07:26Genoveva Uzunova: Why It’s Time to Close the Sex Variable Gap in Healthcare
-
May 13, 2026, 07:09Auston Cherbonneaux: Why Erythritol Just Joined the High-Hazard List
-
May 13, 2026, 06:48Akshat Jain: Transforming Sickle Cell Care With Practical Apheresis Frameworks
-
May 13, 2026, 06:35Dima Shulkin: How Neutrophil Extracellular Traps Shape ACS
-
May 13, 2026, 05:50Danny Hsu: Global Maternal VTE Awareness and Opportunities for Prevention
-
May 13, 2026, 05:50Ney Carter Borges: Clinical Cardiovascular Polygenic Risk Report for 8 Conditions
-
May 13, 2026, 05:49Kalyan Roy: A New Blood Group System Has Been Discovered
-
May 13, 2026, 05:07Azin Alizadehasl: Unraveling DIC in Cancer-Driven Coagulopathy